[ is distinct conversations ]. And live here this morning on c spann span 3, a discussion about transparency and oversight at the food and Drug Administration. Well be hearing from dr. Scott gottlieb starting off the conference. Introductions under way. Efforts to pass and implement the food safety modernization act, focus on medical devices, especially the potential of using the unique device identifier to improve monitoring devices throughout the product lifecycle. We have successfully worked on products 10 to courage innovation particularly around antibiotics and 10 to sure appropriate use of them. We focused on drug safety and transparency in the supply chain and especially on the safety of compounded drugs. Among other things, pew submitted transparency to the task force back in 2010 if the. They touch on some of the topics well be discussing today. Reading the background papers for todays meet regular mind med of a meeting we convened in a room directly above of us here a few yea
Investors. During this portion of the event we hear from jonathan left, chair of the deerfield institute. Its 25 minutes. Thank you so much for coming. Chairman of the deerfield institute, he joined this company in 2013. The company focuses on Venture Capital and structured investments and Bio Technology and pharmaceuticals. Prior for 16 years he led the firms in investment in Bio Technology and pharmaceuticals. Hes been active in policy discussions, served on the executive committee on the board of national Venture Capital association and led that groups Life Sciences efforts. Hes also served on the emerging Company Section board on the Bio Technology board industry organization. Hes served on many nonprofit boards. He is a graduate of Harvard University and the Stanford School of business. And we really appreciate your coming. Thank you. And its great to be here. Were going to talk. Im going to start with a provocative question. Does the Investment Community view the u. S. , food and
The company focuses on Venture Capital and structured investments and Bio Technology and pharmaceuticals. Prior for 16 years he led the firms in investment in Bio Technology and pharmaceuticals. Hes been active in policy discussions, served on the executive committee on the board of national Venture Capital association and led that groups Life Sciences efforts. Hes also served on the emerging Company Section board on the Bio Technology board industry organization. Hes served on many nonprofit boards. He is a graduate of Harvard University and the Stanford School of business. And we really appreciate your coming. Thank you. And its great to be here. Were going to talk. Im going to start with a provocative question. Does the Investment Community view the u. S. , food and Drug Administration as a Necessary Evil or as a critical ally or or Something Else . Thats a great question. I obviously cant speak on the behalf of the entire Investment Community, but i would say overwhelmingly fda is
Thank you so much for coming. Thank you. I forgot to turn my mike on. Jonathan is a partner with deerfield management and chairman of the deerfield institute. He joined this company in 2013. The company focuses on Venture Capital and structured investments and Bio Technology and pharmaceuticals. Prior to joining deerfield for more than 16 years, jonathan was with Warburg Pincus where he led investment in Bio Technology and pharmaceuticals. Hes been active in policy discussions related to health care and medical innovation and served on the executive committee of the board of the national Venture Capital association and led that groups Life Sciences efforts. He has also served on the emerging Company Section board of the Bio Technology industry organization. He has served on many related nonprofit boards including the reagan ucall foundation for the food and Drug Administration. He is a graduate of Harvard University and the Stanford School of business and we thank you for coming. Thank
Set in. If you were a Cherry Blossom youd be frozen by now. Absolutely. Reporter many of the blossoms had hit what is called the puffy white stage. Those petals are already wilting and turning brown. How is it pretty of like this. Reporter temperatures dropped below 24 degrees for a more than five hour stretch overnight. That has the backer service predicting damage to 90 of the blossoms. And we still have two more icy nights to go. It is very sad. You can see they were trying to bloom and then its just not going to happen. Reporter now the horticulturists have been taking cuttings from some of the trees that have been slower to develop like this one. Theyre going to take those branches inside, see if they can force them to bloom and then some time in the next 24 to 48 hours well know blossoms, these slower developing blossoms have been protected inside their kind of woody buds. Live at the tidal basin, bruce leshan, wusa9. Breaking our hearts, bruce. All right. More than three quarter